Statistics from ChinaVenture Investment Group show that since the beginning of 2010, Chinese companies in the Chinese patent medicine industry have completed 34 private equity financing transactions. The accumulated financing amount exceeds RMB 7.366 billion, of which the total scale of the transactions ranked in the top ten is about RMB 4.605 billion, and they are mainly invested in Cerebrovascular disease medication. Liu Yubin, an industry analyst interviewed by a reporter from the China Economic Times, said that for PE institutions, the value of investing in companies focused on cardiovascular, cerebrovascular, anti-tumor, and respiratory diseases is of concern.

In the past four years, the domestic compound market for cardiovascular and cerebrovascular medicines has reached a compound annual average growth rate of 16.7%, which is higher than the compound annual average growth rate of 15.8% for the entire cardiovascular and cerebrovascular medicine market. According to industry insider Liu Jinglong, the scale of anti-tumor drugs has been increasing by more than 30% in recent years. With the ageing of the Chinese population, environmental deterioration and the level of diagnosis and people’s concern for their own health, the share of drugs used in malignant tumors and their derivatives will be Further improve.

At present, there are about 54 proprietary Chinese medicine companies in A-share listed companies, accounting for about one-third of A-listed pharmaceutical companies. The subdivision areas mainly focus on cardiovascular, cerebrovascular, surgical, anti-tumor, gynecological, and orthopedic muscles and other diseases. field.